AEterna Zentaris is a drug development company that specializes in oncology and endocrine therapy.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Quebec
State: Quebec
Zip:
Country: Canada
AEterna Zentaris Inc. is a drug development company specialized in oncology and endocrine therapy. The Company&s;s product pipeline encompasses compounds at all stages of development, from drug discovery through marketed products. The priorities in oncology are its Phase III program with perifosine in multiple myeloma and its Phase II program in multiple cancers, including metastatic colon cancer, as well as Phase II program with AEZS-108 in advanced endometrial and advanced ovarian cancer combined with potential developments in other cancer indications. In endocrinology, the Company&s;s program is the reactivation of a Phase III trial with AEZS-130 (SolorelTM) as a growth hormone (GH) stimulation test for the diagnosis of GH deficiency in adults (AGHD).
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/17/2000
Ticker Symbol:
AEZS
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2015 | Post-IPO Equity | $16.6M | 11/2016 | Post-IPO Equity | $7.6M | 2/2020 | Post-IPO Equity | $4.5M | 2/2021 | Post-IPO Equity | $29.7M | 8/2020 | Post-IPO Equity | $19M | 9/2019 | Post-IPO Equity | $5M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|